Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.61 USD | -1.33% | -11.35% | +18.06% |
Apr. 18 | Verastem Names John Hayslip as Chief Medical Officer | MT |
Apr. 18 | Verastem Oncology Announces Executive Changes | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 30.71M | Capitalization | 243M |
---|---|---|---|---|---|
Net income 2024 * | -130M | Net income 2025 * | -117M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 7.92 x |
P/E ratio 2024 * |
-2.3
x | P/E ratio 2025 * |
-3.27
x | Employees | 73 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.43% |
1 day | -1.33% | ||
1 week | -11.35% | ||
Current month | -18.56% | ||
1 month | -16.65% | ||
3 months | -10.77% | ||
6 months | +39.48% | ||
Current year | +18.06% |
Managers | Title | Age | Since |
---|---|---|---|
Dan Paterson
CEO | Chief Executive Officer | 63 | 10-12-31 |
Daniel Calkins
DFI | Director of Finance/CFO | 37 | 18-11-30 |
Jonathan Pachter
CTO | Chief Tech/Sci/R&D Officer | 66 | 11-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Eric Rowinsky
BRD | Director/Board Member | 67 | 17-05-02 |
John Johnson
BRD | Director/Board Member | 66 | 20-04-22 |
Michael Kauffman
CHM | Chairman | 60 | 12-11-25 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.47% | 4 M€ | -5.15% | - | |
0.02% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-22 | 9.74 | -1.02% | 95,499 |
24-04-19 | 9.84 | -3.81% | 151,397 |
24-04-18 | 10.23 | -5.63% | 66,842 |
24-04-17 | 10.84 | -0.82% | 54,337 |
24-04-16 | 10.93 | -1.26% | 64,334 |
Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.06% | 246M | |
-0.49% | 103B | |
+3.31% | 96.73B | |
+1.66% | 21.31B | |
-16.16% | 21.21B | |
-6.82% | 18.79B | |
-41.41% | 16.37B | |
-22.87% | 13.68B | |
+6.32% | 13.44B | |
+21.46% | 10.98B |
- Stock Market
- Equities
- VSTM Stock